Non-Alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End-Use (Pharma and CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 13, 2026 | Author: Mitiksha Koul | Format:

Market Segmentation

  1. Non-Alcoholic Steatohepatitis Biomarkers Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Serum Biomarkers
    2. Hepatic Fibrosis Biomarkers
    3. Apoptosis Biomarkers
    4. Oxidative Stress Biomarkers
    5. Others
  2. Non-Alcoholic Steatohepatitis Biomarkers Market, By End-Use 2022-2034 (USD MILLION/ Units)
    1. Pharma and CRO Industry
    2. Hospitals
    3. Diagnostic Labs
    4. Academic Research Institutes
  3. Regional Non-Alcoholic Steatohepatitis Biomarkers Market
    1. North America
      1. North America Non-Alcoholic Steatohepatitis Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
      2. North America Non-Alcoholic Steatohepatitis Biomarkers Market By End-Use 2022-2034 (USD MILLION/ Units)
        1. Pharma and CRO Industry
        2. Hospitals
        3. Diagnostic Labs
        4. Academic Research Institutes
      3. U.S.
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      4. Canada
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
    2. Europe
      1. Europe Non-Alcoholic Steatohepatitis Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
      2. Europe Non-Alcoholic Steatohepatitis Biomarkers Market By End-Use 2022-2034 (USD MILLION/ Units)
        1. Pharma and CRO Industry
        2. Hospitals
        3. Diagnostic Labs
        4. Academic Research Institutes
      3. U.K.
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      4. Germany
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      5. France
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      6. Spain
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      7. Italy
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      8. Russia
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      9. Nordic
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      10. Benelux
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      11. Rest of Europe
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
    3. APAC
      1. APAC Non-Alcoholic Steatohepatitis Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
      2. APAC Non-Alcoholic Steatohepatitis Biomarkers Market By End-Use 2022-2034 (USD MILLION/ Units)
        1. Pharma and CRO Industry
        2. Hospitals
        3. Diagnostic Labs
        4. Academic Research Institutes
      3. China
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      4. Korea
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      5. Japan
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      6. India
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      7. Australia
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      8. Singapore
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      9. Taiwan
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      10. South East Asia
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      11. Rest of Asia-Pacific
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
    4. Middle East and Africa
      1. Middle East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
      2. Middle East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market By End-Use 2022-2034 (USD MILLION/ Units)
        1. Pharma and CRO Industry
        2. Hospitals
        3. Diagnostic Labs
        4. Academic Research Institutes
      3. UAE
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      4. Turkey
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      5. Saudi Arabia
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      6. South Africa
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      7. Egypt
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      8. Nigeria
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      9. Rest of MEA
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
    5. LATAM
      1. LATAM Non-Alcoholic Steatohepatitis Biomarkers Market By Type 2022-2034 (USD MILLION/ Units)
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
      2. LATAM Non-Alcoholic Steatohepatitis Biomarkers Market By End-Use 2022-2034 (USD MILLION/ Units)
        1. Pharma and CRO Industry
        2. Hospitals
        3. Diagnostic Labs
        4. Academic Research Institutes
      3. Brazil
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      4. Mexico
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      5. Argentina
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      6. Chile
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      7. Colombia
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes
      8. Rest of LATAM
        1. Serum Biomarkers
        2. Hepatic Fibrosis Biomarkers
        3. Apoptosis Biomarkers
        4. Oxidative Stress Biomarkers
        5. Others
        6. Pharma and CRO Industry
        7. Hospitals
        8. Diagnostic Labs
        9. Academic Research Institutes

We are featured on: